1st Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Firm
Client
Income
—
Expenses
$1,800,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Ensure patient access to behavioral health services and treatments through telehealth; Inflation Reduction Act of 2022 implementation;

LobbyistCovered position, as disclosed
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; FY2024 - Military Construction, Veterans Affairs, and Related Agencies Appropriations;

LobbyistCovered position, as disclosed
WILLIAM PATRICK HIBBS —
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Office of Natl Drug Control Policy (NDCP); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: S. 464 (118th), H.R. 2163 (118th)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; Expand funding and flexibility to address all substance use disorders;

LobbyistCovered position, as disclosed
WILLIAM PATRICK HIBBS —
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Executive Office of the President (EOP); Justice, Dept of (DOJ); Veterans Affairs, Dept of (VA); SENATE; HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.